Transverse Myelitis Trial, Recruiting NCT06312644 Sponsor: Alexion Pharmaceuticals, Inc. Condition: Transverse Myelitis
Back to Transverse Myelitis

Transverse Myelitis Trial, Recruiting

NCT06312644
Recruiting Not Applicable 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must have a confirmed pregnancy (either current or past) that qualifies for the study.
  • You (or your parent/legal guardian if you are a minor) must be willing and able to sign a consent form before joining.
  • You must be willing to share your contact information with the study team.
  • You must be willing to allow your doctor(s) to share your medical information and your baby's medical information with the study, where local rules allow.
  • You must have a medical condition for which the drug Ultomiris has been officially approved, confirmed by a doctor or medical records.
  • You must have been treated with Ultomiris at some point during a specific time window — this includes before conception, during pregnancy, or while breastfeeding (even if exact dates are unknown, an estimate of timing is acceptable).
  • Your use of Ultomiris must have followed the official prescribing guidelines in your country.

Who may not be able to join:

  • People who are not able to give their own consent or agreement to participate — for example, those with severe psychiatric conditions or severe intellectual disabilities — are not eligible for this study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sydney Williams, North American Coordinating Center (NACC)

Phone: 1-855-752-2356

Australian sites

Research Site, Melbourne, Victoria

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Alexion Pharmaceuticals, Inc.
Registry
ClinicalTrials.gov
Start date
16 December 2024
Est. completion
11 July 2034

Where this trial is recruiting

🇦🇺 Australia 🇫🇷 France 🇩🇪 Germany 🇮🇹 Italy 🇰🇷 South Korea 🇬🇧 United Kingdom 🇺🇸 United States

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Pregnancy Complications; Maternal Complications; Fetal/Infant Outcomes

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov